Whats Next
Clinical Safety Concerns With Alternating GLP-1 Medications Switching between semaglutide and tirzepatide mid-treatment creates several medical risks
Agha-Hosseini F, Shirzad N, Moosavi MS
doi: 10.1016/S0140-6736(02)07340-3 Summary Keywords Prader-Willi syndrome (PWS), genotype-phenotype correlation, growth hormone (GH), metabolic syndrome, hypogonadism, bone metabolism, type 2 diabetes, thyroid Citation Madeo SF, Zagaroli L, Vandelli S, Calcaterra V, Crin A, De Sanctis L, Faienza MF, Fintini D, Guazzarotti L, Licenziati MR, Mozzillo E, Pajno R, Scarano E, Street ME, Wasniewska M, Bocchini S, Bucolo C, Buganza R, Chiarito M, Corica D, Di Candia F, Francavilla R, Fratangeli N, Improda N, Morabito LA, Mozzato C, Rossi V, Schiavariello C, Farello G, Iughetti L, Salpietro V, Salvatoni A, Giordano M, Grugni G and Delvecchio M (2024) Endocrine features of Prader-Willi syndrome: a narrative review focusing on genotype-phenotype correlation
Cohort 2 (Prevalent GLP-1 RA Users) Cohort 2 members comprised the following categories of patients: prior GLP-1 RA users who switched from other GLP-1 RAs to dulaglutide or semaglutide during the patient selection time window (prior GLP-1 RA user but nave to dulaglutide and/or semaglutide) and prior users of dulaglutide and semaglutide who received dulaglutide or semaglutide during the patient selection window (prior GLP-1 RA user not nave to dulaglutide and/or semaglutide)
When done by certified dermatologists at our clinic, the method is secure and clinically supervised
